✅ 9 criteria passed
❌ 2 criteria to solve
Boost thepharmaletter.com's SEO with Kontactr's Guest Posting.
Secure high-authority, do-follow backlinks from our trusted site—DA45 domain authority and PA55 homepage and blog pages.
Perfect for webmasters seeking higher search rankings and increased organic traffic.
Simple, quick, and effective.
opens a new window
Authoritative Pharma and Biotech News - The Pharma Letter
https://thepharmaletter.com
Up to date news for the pharmaceutical and biotechnology industries - The Pharma Letter
https://thepharmaletter.com
Authoritative Pharma and Biotech News - The Pharma Letter
Up to date news for the pharmaceutical and biotechnology industries - The Pharma Letter
Great, a redirect is in place to redirect traffic from your non-preferred domain. All versions of your page point to the same URL.
| Attribute | Value |
| ⓘ author | The Pharma Letter |
| ⓘ viewport | width=device-width, initial-scale=1.0, user-scalable=yes |
ⓘ The owner has associated the following topics to the website.
ⓘ The results of our semantic analysis are shown below using the website's language.
They are the main concepts covered by thepharmaletter.com.
Each concept has a confidence score. The higher it is, the more important the topic is relative to the page.
| Topics | |
The Pharma Letter Confidence: 88% 
|
|
Biotechnology Confidence: 76%
|
|
Pharmaceutical industry Confidence: 72%
|
|
Industry Confidence: 66% 
|
✅ thepharmaletter.com website speed is normal. Page speed is important for visitors and search engines.
Get insights to improve your page loading time.
This domain loads at the median speed of 1.8 seconds.
thepharmaletter.com is faster than approximately 48 percent of the web. Your website page speed needs to be as fast as you can make it, without compromising the customer experience.
A good goal to achieve is a loading time of 2 seconds on desktop and mobile devices.
ⓘ This website is ranked #240.992 by Alexa.
This rank is traffic based. The lower the rank is, the better the domain is ranked.
| Country | Rank |
 United States of America |
#103.642 |
 India |
#68.385 |
Mobile Rendering
This website seems to be optimized for Mobile Visitors.
Phone
Tablet
A good text to HTML ratio is anywhere from 25 to 70%.
This percentage refers to the visible text ratio, as opposed to HTML elements, image tags and other non-visible information.
Great, we found headings on this page.
| Top level heading |
| The pharma letter |
| Europe can build on success in children’s rare diseases, says sanofi exec |
For a better readability, only the first 20 <H2> tags are shown below.
| 2nd level heading |
| Top news stories |
| Top ınsights stories |
| Top pricingstories |
| Top conference news stories |
| Top therapy areas stories |
| Rare diseases: |
| From our correspondent: |
| ınterview: |
| Expert view: |
| Analysis |
| Latest ın brief |
| Latest pharmaceutical news |
| Latest biotechnology news |
| Latest generics news |
| Latest biosimilars news |
| Top 5 stories (2) |
| Company |
| Fda blog |
| Boardroom |
| Mergers & acquisitions |
For a better readability, only the first 20 <H3> tags are shown below.
| 3rd level heading |
| ılluminating monogenic diabetes |
| Latin america’s pharma industry staying optimistic despite economic uncertainty (2) |
| ıksuda ceo says british biotech is buoyant, brexit notwithstanding |
| Five emerging trends impacting the role of pharmaceutical distributors |
| Gsk company focus: turning the ship around |
| Sunovion refiles nda for apomorphine sublingual film |
| Takeda’s alunbrig continues to show superiority over xalkori in alk+nsclc |
| Fresenius kabi supplies six critical-care drugs to novaplus program |
| Teva and celltrion debut truxima, first rituxan biosimilar, in usa |
| Merck & co to pay up to $576 million for calporta therapeutics |
| Fda approves beigene’s therapy to treat rare form of lymphoma |
| Anaptysbio's loss is dermira's gain after etokimab failure |
| Novartis sets out new strategy to broaden access to medicines in sub-saharan africa |
| Study shows variations in drug prices across countries |
| Biomarin submits ema filing for first hemophilia gene therapy |
| Sigh of relief as bristol-myers finally completes buy of celgene |
| ındia’s top-10 selling drugs dominated by diabetes products |
| Gilead’s kite unit adds industry vets to its executive team (2) |
| Antengene |
| ıs the fda walking the talk with supporting innovation? |
We found 36 images on this website.
2
ALT attributes are missing on your image tags.
| Image | Image URL | Occurrences |
| https://www.facebook.com/tr?id=416152832524003&ev=PageView&noscript=1 | 1 | |
| https://dc.ads.linkedin.com/collect/?pid=645873&fmt=gif | 1 |
Alternative text allows you to add a description to an image.
Google rely on alternative text attributes to determine relevance to a search query. Alternative text also makes an image more likely to appear in a Google image search.
It looks like you're missing alternative text for 2 images on thepharmaletter.com. Check your website to make sure it's specified for each image on the page.
2 of which have the nofollow attribute, meaning that their destination should not be afforded any additional weight or ranking by search engines.
For a better readability, only the first 50 internal links are shown below.
| ⓘ Domain Registrar | 123-REG LIMITED |
| ⓘ Registration Date | 08/06/2009 15 years, 3 months, 13 days ago |
| ⓘ Last Modified | 07/16/2019 5 years, 4 months, 4 days ago |
| ⓘ Expiration Date | 08/06/2020 Expired |
| Host | IP Address | Country |
| paul.ns.cloudflare.com | 173.245.59.135 | United States |
| zara.ns.cloudflare.com | 173.245.58.148 | United States |
| Domain |
Others (33.2%)
SOCIAL MEDIA PRESENCE
You're doing quiet good on social media!
Social shares are a key signal, among many others, that search engines use to evaluate the rankings of a website. Asking people to share your pages, adding visible social share buttons and make great quality content are 3 of the most powerful ways to grow your social presence.